Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
7,8 Though safety and efficacy data is not yet available, an upcoming phase 1 study looking at ivermectin in patients with triple negative breast cancer (in combination with balstilimab, a chemotherapeutic agent) plans to evaluate dosing at 30, 45, or 60mg daily on days 1-2, 8-10, and 15-17 in a 21 day cycle until disease progression or intolerance
No wasted peptide
mice treated concurrently with IPC (3 doses/ week) at 50 mg/kg body weight and CoQ 10 (300 mg/kg b.wt) daily for 4 weeks
Akbari-Kordkheyli V, Abbaszadeh-Goudarzi K, Nejati-Laskokalayeh M, Zarpou S,Khonakdar-Tarsi A
US$ 21.24
US$ 28.58
US$ 28.37
US$ 28.16
US$ 25.48
US$ 23.86
US$ 20.58
